Faratian Dana, Munro Alison, Twelves Christopher, Bartlett John M S
Division of Pathology and Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Edinburgh, UK.
Histopathology. 2009 Jan;54(2):254-7. doi: 10.1111/j.1365-2559.2008.03191.x.
Membranous and cytoplasmic Ki67 immunoreactivity has recently been observed in a number of histopathological entities, but frequency of occurrence and relationship to prognosis in more common cancers have not been described. The aim was to describe the pattern and frequency of membranous/cytoplasmic Ki67 in a cohort of invasive breast carcinomas, and their associations with grade, HER2 amplification and oestrogen receptor (ER) expression.
Three hundred and twenty-two cases of invasive ductal carcinoma were assessed for histological grade, Ki67 (MIB-1 clone) proliferation index and pattern of immunoreactivity, ER expression by immunohistochemistry, and HER2 amplification status by fluorescence in situ hybridization. Overall, 26/322 (8%) breast carcinomas showed membranous/cytoplasmic Ki67, and expression was significantly associated with grade 3, HER2-amplified and ER- tumours. Membranous/cytoplasmic Ki67 was not, however, an independent prognostic factor on multivariate analysis.
Membranous/cytoplasmic Ki67 identifies a group of breast carcinomas that may be important to consider separately in prognostic and predictive studies. The mechanism of subcellular Ki67 relocalization remains elusive and further studies are required to establish both the cause and effect of this unusual pattern of Ki67 immunoreactivity.
近期在多种组织病理学实体中观察到膜性和胞浆性Ki67免疫反应性，但在更常见癌症中的发生频率及其与预后的关系尚未见描述。本研究旨在描述一组浸润性乳腺癌中膜性/胞浆性Ki67的模式和频率，以及它们与分级、HER2扩增和雌激素受体（ER）表达的相关性。
对322例浸润性导管癌进行组织学分级、Ki67（MIB-1克隆）增殖指数和免疫反应性模式评估，通过免疫组织化学检测ER表达，通过荧光原位杂交检测HER2扩增状态。总体而言，26/322（8%）例乳腺癌显示膜性/胞浆性Ki67，其表达与3级、HER2扩增和ER阴性肿瘤显著相关。然而，在多变量分析中，膜性/胞浆性Ki67并非独立的预后因素。
膜性/胞浆性Ki67识别出一组乳腺癌，在预后和预测研究中可能需要单独考虑。亚细胞Ki67重新定位的机制仍不清楚，需要进一步研究以确定这种不寻常的Ki67免疫反应性模式的因果关系。
